Education
About Us
Working with TipRanks
Follow Us
Xenon Pharmaceuticals (XENE)
:XENE
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 9.43M | $ 18.44M | $ 32.17M |
| Gross Profit | $ 0.00 | $ -167.51M | $ -96.33M | $ -57.03M | $ -18.36M |
| Operating Income | $ -279.30M | $ -214.05M | $ -129.14M | $ -78.99M | $ -31.30M |
| EBITDA | $ -279.30M | $ -210.51M | $ -127.52M | $ -78.09M | $ -27.97M |
| Net Income | $ -234.33M | $ -182.39M | $ -125.37M | $ -78.88M | $ -28.84M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 626.90M | $ 638.08M | $ 592.09M | $ 551.77M | $ 177.00M |
| Total Assets | $ 798.14M | $ 964.80M | $ 754.15M | $ 572.01M | $ 189.19M |
| Total Debt | $ 9.02M | $ 10.90M | $ 10.44M | $ 8.26M | $ 3.31M |
| Net Debt | $ -133.70M | $ -137.74M | $ -46.81M | $ -167.43M | $ -41.69M |
| Total Liabilities | $ 43.24M | $ 36.88M | $ 32.65M | $ 21.97M | $ 17.83M |
| Stockholders' Equity | $ 754.90M | $ 927.92M | $ 721.50M | $ 550.03M | $ 171.35M |
| Cash Flow | |||||
| Free Cash Flow | $ -181.39M | $ -150.94M | $ -101.32M | $ -71.55M | $ -50.76M |
| Operating Cash Flow | $ -181.39M | $ -145.33M | $ -98.43M | $ -69.50M | $ -48.12M |
| Investing Cash Flow | $ 165.00M | $ -117.17M | $ -296.00M | $ -246.77M | $ -16.82M |
| Financing Cash Flow | $ 12.13M | $ 353.52M | $ 278.47M | $ 447.54M | $ 85.80M |